Checklist reduces adverse pregnancy outcomes in patients with RA
The risk can be reduced to that of the general population, researchers say
Pregnant women with RA can reduce their risk of adverse pregnancy outcomes to that of the general population if they follow an “ideal clinical pathway”, Italian researchers say.
They have developed a set of healthcare quality indicators for pregnancy in RA based, in part, on guidance for other rheumatic diseases.
These include four diagnostic tests in the 18 months before conception:
They note, however, that there should be no exposure to methotrexate or leflunomide from six months prior to conception, no exposure to biologics during the pregnancy and at least one rheumatology consultation during the pregnancy.
